The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study

The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study Mary Kathryn Abel, Amy S Shui, A. Jo Chien, Hope S. Rugo, Michelle Melisko, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-1322653/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Purpose : To evaluate whether patients with ILC are more likely to have discordant clinical and genomic risk than those with IDC when using the 21-gene recurrence score (RS), and to assess overall survival outcomes of patients with 1-3 positive nodes and RS ≤ 25 with and without chemotherapy, stratified by histology. Methods : We performed a cohort study using the National Cancer Database and included patients with hormone receptor positive, HER2 negative, stage I-III invasive breast cancer who underwent 21-gene RS testing. Our primary outcome was rate of discordant clinical and genomic risk status by histologic subtype. Propensity score matching was used to compare 60-month overall survival in individuals with 1-3 positive nodes and RS £ 25 who did and did not receive chemotherapy. Results : 186,867 patients were included in our analysis, including 37,685 (20.2%) patients with ILC. There was a significantly higher rate of discordant clinical and genomic risk in patients with ILC compared to IDC. Among patients with 1-3 positive nodes and RS ≤ 25, there was no significant difference in survival between those who did and did not receive chemotherapy in the IDC or ILC cohorts. Unadjusted exploratory analyses of patients under age 50 with 1-3 positive nodes and RS ≤ 25 showed improved overall survival in IDC patients who received chemotherapy, but not among those with ILC. Conclusion : Our findings highlight the importance of lobular-specific tools for stratifying clinical and genomic risk, as well as the need for histologic subtype-specific analyses in randomized trials. invasive lobular carcinoma invasive ductal carcinoma chemotherapy 21-gene recurrence score Figures Figure 1 Figure 2 Figure 3 Introduction Despite major advances in the treatment of breast cancer, personalizing therapy to reduce recurrence risk while minimizing harm remains a challenge. Recommendations for treatment such as adjuvant chemotherapy rely upon multiple factors, including patient characteristics and overall health status, tumor features, and often molecular assays such as the 70-gene signature or the 21-gene Recurrence Score (RS) [ 1 – 3 ]. When patient and tumor factors suggest a high risk of recurrence, patients are deemed to have high “clinical” risk, and chemotherapy may be considered. Similarly, when molecular assays suggest a high risk of recurrence, tumors are considered to have high “genomic” risk, and patients with these high-risk tumors are predicted to benefit from chemotherapy. However, when clinical and genomic risk are discordant, decisions about the efficacy of chemotherapy become more difficult. In the recently published RxPONDER trial, chemotherapy did not improve invasive disease-free survival in clinically high-risk post-menopausal patients with low genomic risk (based on RS ≤ 25), although benefit was seen in those who were pre-menopausal [ 4 ]. These findings illustrate some of the challenges of treatment selection for those with discordant clinical and genomic risk. We previously showed that such discordant risk status disproportionately affects patients with invasive lobular carcinoma (ILC) compared to invasive ductal carcinoma (IDC) when genomic risk is evaluated with 70-gene signature testing [ 5 ]. As the second most common histologic subtype of breast cancer, ILC is thought to have a more indolent course but often presents at higher stages with considerable cumulative risk of late recurrence [ 6 – 11 ]. We therefore sought to investigate rates of discordant clinical and genomic risk by histologic subtype in patients who underwent RS testing in the National Cancer Database. Specifically, we evaluated the following questions: (1) whether patients with ILC are more likely to have discordant clinical and genomic risk than those with IDC using the 21-gene RS; (2) whether use of chemotherapy differs by histologic subtype stratified by clinical and genomic risk category; and (3) whether patients with 1-3 positive nodes and RS ≤ 25 have different overall survival outcomes with or without adjuvant chemotherapy stratified by histologic subtype. Methods Data Source and Study Cohort Our study cohort consisted of patients in the National Cancer Database (NCDB). The NCDB is a national comprehensive clinical surveillance resource and represents over 70% of all newly diagnosed cancer cases in the United States [ 12 , 13 ]. Participants User Files from 2010-2016 were used in our analysis. Due to the de-identified nature of the public-access user files, the study did not require institutional review board approval. We limited our analysis to patients with invasive HR positive and human epidermal growth factor-receptor 2 (HER2) negative tumors with an available 21-gene RS result. We excluded patients with stage IV disease, those who received neoadjuvant therapy, individuals who did not undergo surgery for breast cancer, and those who were missing critical clinical information including histologic subtype, tumor grade, number of positive lymph nodes on pathology, tumor size, and timing of chemotherapy or endocrine therapy. Clinical Measures and Outcomes Our primary outcome was the rate of discordant clinical and genomic risk status by histologic subtype. We assigned clinical risk using a modified Adjuvant! Online calculator as described in the MINDACT trial; we also categorized patients by number of positive lymph nodes on surgical pathology (0, 1-3, or >3 nodes) [ 3 , 4 , 14 – 16 ]. The modified Adjuvant! Online risk score includes tumor size, tumor grade, and number of positive lymph nodes identified at surgery; those with a 92% or greater probability of breast-cancer specific survival at 10 years without chemotherapy were deemed to have low clinical risk [ 17 , 18 ]. We assigned genomic risk using the 21-gene RS result, with RS > 25 considered as high genomic risk and RS ≤ 25 as low genomic risk, consistent with RxPONDER. Histologic subtype was determined by defined codes in the NCDB. The ILC cohort included codes for ILC or mixed ILC/IDC (histology codes 8520 and 8524 if behavior was invasive). The IDC cohort comprised codes for IDC or invasive mammary carcinoma not otherwise specified (histology codes 8500, 8501, 8502, 8503, and 8523 if behavior was invasive). Menopausal status was approximated using age under 50 years (pre-menopausal) and over 50 years (post-menopausal) and included as a predictor in our model. Additionally, the Charlson-Deyo Co-Morbidity Index was used as a marker of severity of co-morbid conditions. The Charlson-Deyo Co-Morbidity Index is a weighted score from 0-3 derived from multiple comorbid conditions, including myocardial infarction, diabetes, and renal disease, with higher score reflecting more comorbid disease [ 19 – 21 ]. Statistical Analysis Patient characteristics were described and differences between histologic subtype were evaluated using chi-square tests for categorical variables and t-tests for continuous variables. Additionally, the frequency of patients in each of the four clinical and genomic risk categories (clinical high/genomic low, clinical low/genomic low, clinical high/genomic high, clinical low/genomic high) was described by histologic subtype, with chi-square testing used to compare the clinical high/genomic low risk cohort compared to other risk categories combined and across all four risk categories. We also performed subgroup analyses evaluating concordance of genomic and clinical risk by categorical nodal status, histology, and age. Receipt of chemotherapy stratified by histology, nodal status, RS, and age was also assessed. All analyses were pre-specified. Finally, propensity score matching was used to compare 60-month overall survival in individuals who did and did not receive chemotherapy among patients with 1-3 positive nodes and RS ≤ 25, stratified by histology. A greedy, fixed 1:1 matching method was used, and patients were matched by age at diagnosis in years, pathologic stage of disease (stage 2/3 vs. stage 1), and facility type. The upper limit of the absolute values of weighted matched standardized mean differences was set at 0.2. While we planned a pre-specified propensity score matched analysis evaluating the relationship between chemotherapy and overall survival in the subgroup of women aged under 50 years, with 1-3 positive nodes, and RS ≤ 25, there were too few patients to allow for matching. We therefore performed exploratory analyses evaluating overall survival with and without chemotherapy using the log-rank test in this subgroup of women, stratified by histology; we also used the Cox proportional hazards model to evaluate overall survival both unadjusted and adjusted for Charlson-Deyo Co-Morbidity Index. Hypothesis tests were two-sided, and the significance threshold was set to 0.05. Statistical analyses were performed using Stata 16 and SAS version 9.4. Results A total of 2,696,734 patients with breast cancer were included in the original NCDB database. After excluding patients based on the criteria previously described, there were 186,867 patients with stage I-III, HR positive, HER2 negative disease without neoadjuvant therapy who underwent breast surgery and received 21-gene RS testing that were included in our analysis (Figure 1 ). Of these, 149,182 (79.8%) patients had IDC, and 37,685 (20.2%) patients had ILC. ILC versus IDC Cohorts Patients in the ILC cohort were slightly older than those in the IDC cohort (mean age 60.5 years versus 58.9, p<0.001). Additionally, they were more likely to present with higher stage disease and underwent mastectomy at higher rates (Table 1 ). The ILC tumors were significantly less likely to be grade 3, and overall chemotherapy was used less often in the ILC cohort compared to those with IDC. There was also a statistically significant difference in Charlson-Deyo score between the ILC and IDC cohorts, with ILC patients as more likely to have a Charlson-Deyo score of 0 compared to those with IDC (85.0% vs. 84.5%, p=0.015). Table 1 Clinicopathologic characteristics of study cohort. ILC (N = 37,685) IDC (N = 149,182) P-Value Age at diagnosis (years), mean (SD) 60.5 (10.0) 58.9 (10.6) < 0.001 Pathologic stage, n (%) I II III 21,384 (56.7) 15,302 (40.6) 999 (2.7) 104,748 (70.2) 43,194 (29.0) 1,240 (0.8) 3 positive 30,401 (80.7) 6,869 (18.2) 415 (1.1) 123,470 (82.8) 24,919 (16.7) 793 (0.5) <0.001 Tumor grade, n (%) 1 2 3 9,451 (25.1) 25,403 (67.4) 2,831 (7.5) 43,276 (29.0) 78,871 (52.9) 27,035 (18.1) < 0.001 Clinical risk, n (%) Low High 21,464 (57.0) 16,221 (43.0) 96,060 (64.4) 53,122 (35.6) 25 34,534 (91.6) 3,151 (8.4) 125,030 (83.8) 24,152 (16.2) < 0.001 Surgical therapy, n (%) Lumpectomy Mastectomy 21,373 (56.7) 16,312 (43.3) 102,467 (68.7) 46,715 (31.3) < 0.001 Adjuvant therapy, n (%) Chemotherapy Endocrine Therapy 6,383 (17.3) 35,161 (94.6) 33,534 (22.9) 137,003 (93.4) < 0.001 < 0.001 Charlson-Deyo Score, n (%) 0 1 2 ≥3 32,039 (85.0) 4,629 (12.3) 799 (2.1) 218 (0.6) 126,007 (84.5) 18,834 (12.6) 3,312 (2.2) 1,029 (0.7) 0.015 Legend : ILC = invasive lobular carcinoma; IDC = invasive ductal carcinoma; RS = recurrence score Clinical and Genomic Risk Discordance We found a significantly higher rate of discordant clinical and genomic risk in patients with ILC compared to IDC. Patients with ILC were more likely to have high clinical risk by modified Adjuvant! Online than those with IDC (43% versus 35.6%, p<0.001, Table 1 ). Consistent with this finding, those with ILC were less likely to be node negative than those with IDC (80.7% versus 82.8%, p 25 in ILC patients of 8.4% compared to 16.2% in IDC patients (p<0.001). Together, this resulted in significantly higher rates of discordant clinical and genomic risk, with 37.8% of the ILC group being clinical high/genomic low compared to 24.9% of the IDC group (p 25. ILC (n = 37,685) IDC (n = 149,182) P-Value 1 P-Value 2 Clinical high/21-gene RS ≤ 25 14,253 (37.8) 37,126 (24.9) < 0.001 25 1,968 (5.2) 15,996 (10.7) Clinical low/21-gene RS > 25 1,863 (4.9) 10,982 (7.4) Legend : ILC = invasive lobular carcinoma, IDC = invasive ductal carcinoma. 1 P-value from chi square comparing clinical high / genomic low compared to other risk categories combined. 2 P-value from chi square comparing across all four risk categories. Within the group of patients with 1-3 positive nodes, patients with ILC were significantly more likely to have a RS ≤ 25 compared to those with IDC (92.5% versus 85.8% respectively, p3 positive nodes, with the vast majority of ILC patients in this group (90.1%) having a RS ≤ 25 compared to 78.3% in the IDC group (p<0.001, Table 3 ). Interestingly, among patients under the age of 50, ILC patients remained significantly more likely to have RS ≤ 25 than those with IDC across all nodal involvement categories. In patients under age 50 with 1-3 positive nodes, low RS occurred in 94.8% of ILC group versus 85.1% of IDC group; among the small number of patients with >3 positive nodes, low RS occurred in 94.7% of ILC group versus 70.6% of IDC group (both p<0.001, Table 3 ). Table 3 Breakdown of nodal status by histology and 21-gene recurrence score in all patients (top) and for those with age less than 50 years (bottom). All Patients ILC Overall (n) IDC Overall (n) ILC 21-Gene RS ≤ 25 (n [%]) IDC 21-Gene RS ≤ 25 (n [%]) P-Value 1 Node Negative 30,401 123,470 27,804 (91.5%) 103,039 (83.5%) < 0.001 1-3 Positive Nodes 6,869 24,919 6,356 (92.5%) 21,370 (85.8%) 3 Positive Nodes 415 793 374 (90.1%) 621 (78.3%) < 0.001 Patients Age < 50 Years ILC Overall (n) IDC Overall (n) ILC 21-Gene RS ≤ 25 (n [%]) IDC 21-Gene RS ≤ 25 (n [%]) P-Value 1 Node Negative 4,911 26,038 4,644 (94.6%) 22,016 (84.6%) < 0.001 1-3 Positive Nodes 1,120 4,996 1,062 (94.8%) 4,251 (85.1%) 3 Positive Nodes 57 163 54 (94.7%) 115 (70.6%) < 0.001 Legend : ILC = invasive lobular carcinoma, IDC = invasive ductal carcinoma, RS = recurrence score. 1 P-value from chi square comparing ILC 21-gene RS ≤ 25 and 21-gene IDC RS ≤ 25 across nodal categories. Chemotherapy Use We then evaluated the receipt of chemotherapy by histology, nodal status, RS category, and age. Among patients with RS ≤ 25, there was no difference in receipt of chemotherapy by histology across the node negative, 1-3 positive nodes, and >3 positive nodal groups (Figure 2 ). However, among patients with RS > 25, those with ILC were significantly less likely to receive chemotherapy than those with IDC among patients with negative nodes or 1-3 positive nodes (both p 25, chemotherapy was used significantly more often in patients under 50 years old compared to those age 50 years or older, in both ILC and IDC groups. However, among clinically high risk patients with RS > 25 and age over 50 years, those with ILC were still less likely to receive chemotherapy than those with IDC (63.3% versus 74.8%, p 25, 88.7% of patients were age 50 years or older, and 63.3% received chemotherapy compared to 80.5% of those under age 50 years (p 25, 78.2% of patients were age 50 years or older, and 74.8% received chemotherapy compared to 88.2% of those under age 50 years (p<0.001). Overall Survival Outcomes Finally, we performed a propensity score matched analysis to compare overall survival in individuals who received chemotherapy compared to those who did not receive chemotherapy by histology among those with 1-3 positive nodes and RS ≤ 25, including patients of all ages. The absolute values of the weighted matched standardized mean differences were less than the recommended upper limit of 0.2, and all weighted matched variance ratios were between 0.5 and 2. Among patients with IDC, there was no statistically significant difference in survival between those who did and did not receive chemotherapy (stratified log-rank test p=0.278, Figure 3a). Similarly, for patients with ILC, survival between those who did receive chemotherapy and those who did not receive chemotherapy was not significantly different from one another (stratified log-rank test p=0.532, Figure 3b). There were too few patients under the age of 50 years to perform a propensity score matched analysis, so exploratory results from unmatched survival analyses are reported. For women under age 50, with 1-3 positive nodes, and RS ≤ 25, unadjusted analysis showed that chemotherapy was associated with a significant improvement in overall survival for those with IDC (hazard ratio [HR] 0.44, 95% confidence interval [CI] 0.22-0.86, p=0.016) but not for those with ILC (HR 0.54, 95% CI 0.14-2.18, p=0.39). The association between chemotherapy and improved overall survival in those with IDC persisted when adjusted for Charlson-Deyo Index (HR 0.44, 95% CI 0.22-0.85, p=0.016). There was no statistical interaction between chemotherapy and histology on overall survival. Discussion In this study of 186,867 patients with HR positive, HER2-negative invasive breast cancer who underwent 21-gene RS testing in the National Cancer Database, we found that patients with ILC have higher rates of discordant clinical and genomic risk than those with IDC. This finding is consistent with our prior work, which showed higher rates of discordant clinical and genomic risk in ILC patients using the 70-gene signature [ 5 ]. Additionally, we found that ILC patients with 1-3 positive nodes were significantly more likely to have RS ≤ 25 compared to those with IDC, in both those under age 50 years and those age 50 years or older. Among those with RS ≤ 25, there was no difference in receipt of chemotherapy by histology regardless of nodal involvement. However, among those with RS >25, those with ILC were significantly less likely to receive chemotherapy than those with IDC among patients with negative nodes or 1-3 positive nodes. While these findings are consistent with our prior study, which showed lower rates of chemotherapy use in patients with high clinical risk ILC and high genomic risk as defined by 70-gene signature testing, they are nonetheless surprising given the general acceptance of chemotherapy in the setting of RS > 25 and did not appear to be driven by older age in the ILC group [ 5 , 14 ]. These findings may reflect hesitation on the part of clinicians and patients to utilize chemotherapy in ILC, where multiple studies have shown less benefit in the neoadjuvant and adjuvant settings [ 22 , 23 ]. Together, this illustrates the treatment dilemma that clinicians and patients face: while patients with ILC are more likely to have high clinical risk, which portends increased risk of recurrence without chemotherapy, genomic assays and reported series suggest decreased chemotherapy benefit [ 24 ]. We did not demonstrate any effect of chemotherapy on overall survival among patients with 1-3 positive nodes and RS ≤ 25 in our propensity score matched analyses, regardless of histologic subtype. Interestingly, we did find an association between chemotherapy and overall survival in unmatched analysis of IDC patients under age 50 with 1-3 positive nodes and RS ≤ 25, but not among those under age 50 with ILC. Given the retrospective nature of this analysis, differences in patient selection for receiving chemotherapy likely contribute to chemotherapy related outcomes. While we attempted to account for potential confounders in treatment selection by using propensity score matching by age at diagnosis, pathologic stage, and facility type, it is unlikely that we were able to fully adjust for potential bias between the chemotherapy and non-chemotherapy groups. This bias is greater in our exploratory unmatched analysis in patients under age 50, which showed a significant improvement in overall survival among IDC patients who received chemotherapy compared to those who did not but no difference in those with ILC. There are several potential explanations for the findings of our exploratory analyses. One possibility is that among those under age 50 with 1-3 positive nodes and RS ≤ 25, the overall survival difference observed in the IDC group resulted from patient selection bias and not chemotherapy effect. Another explanation is that we were unable to detect an overall survival benefit in the ILC patients under age 50, with 1-3 positive nodes, and RS ≤ 25 because of small numbers in this subgroup. Lastly, it is possible that chemotherapy improves overall survival in IDC patients but not ILC patients under the age of 50 with 1-3 positive nodes and RS ≤ 25; for this reason, reporting of long-term and overall survival outcomes by histologic subtype from trials such as RxPONDER is needed. While the RxPONDER trial showed a significant improvement in invasive disease-free survival in patients under age 50 who had 1-3 positive nodes and RS ≤ 25 who received chemotherapy, we cannot directly compare our results since the National Cancer Database lacks recurrence endpoints. It is important to note that for patients with HR positive HER2 negative tumors, and ILC especially, recurrence events and consequently impact on overall survival can happen at later timepoints, highlighting the need for longer term follow-up [ 25 , 26 ]. Additionally, we lacked data on type of endocrine therapy which likely impacts outcomes. This study has many strengths, including the use of a relatively large numbers of ILC patients, and is now the second study to demonstrate that patients with ILC have high rates of discordance between clinical and genomic risk based on widely used molecular assays. While many studies show that ILC tumors have lower response rates to chemotherapy in the neoadjuvant setting, and less benefit from chemotherapy in the adjuvant setting, there may still be a subset of chemotherapy sensitive ILC cases. Recent work has identified genomic signatures that identify subtypes within ILC, suggesting heterogeneity within this tumor type [ 27 , 28 ]. The high incidence of high clinical risk among patients with ILC highlights the need for both more effective therapies, and potentially ILC specific prediction tools. More broadly, improving outcomes for these patients with ILC will require not only equitable enrollment of ILC patients into breast cancer clinical trials, but also histologic subtype specific reporting of trial results. Declarations Amy M. Shui is part of the Biostatistics Core that is generously supported by the UCSF Department of Surgery. Funding Dr. Rita A. Mukhtar is supported by National Cancer Institute Award K08CA256047. The other authors declare that no funds, grants, or other support were received during the preparation of this manuscript. Competing Interests Dr. A. Jo Chien receives research funding from Merck, Puma, Amgen, and Seattle Genetics. Dr. Hope S. Rugo receives research support for clinical trials through the University of California from Pfizer, Merck, Novartis, Lilly, Roche, Odonate, Daiichi, Seattle Genetics, Macrogenics, Sermonix, Astra Zeneca, OBI, Gilead, and Ayala. She has also received honoraria from Puma, Samsung, and Napo. Dr. Michelle Melisko receives research funding from Astra Zeneca, Novartis, KCRN Research, and Puma and consulting fees from Biotheranostics. Dr. Baehner is the Chief Medical Officer of Precision Oncology at Exact Sciences. The remaining authors declare no competing interests. Author Contributions All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Mary Kathryn Abel, Amy M. Shui, and Dr. Rita A. Mukhtar. The first draft of the manuscript was written by Mary Kathryn Abel and Dr. Rita A. Mukhtar, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. Data Availability The data that support the findings of this study are available from the National Cancer Database (NCDB), but restrictions apply to the availability of these data, which were used under license for the current study and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the NCDB. Ethics Approval Our study was deemed exempt by University of California, San Francisco institutional review board. Consent to Participate Not applicable Consent to Publish Not applicable References Van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536. https://doi.org/10.1038/415530a van de Vijver MJ, He YD, van ’t Veer LJ et al (2002) A Gene-Expression Signature as a Predictor of Survival in Breast Cancer. N Engl J Med 347:1999–2009. https://doi.org/10.1056/nejmoa021967 Cardoso F, van ’t Veer L, Poncet C et al (2020) MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients. In:Journal of Clinical Oncology. p506 Kalinsky K, Barlow WE, Gralow JR et al (2021) 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med 385:2336–2347. https://doi.org/10.1056/NEJMOA2108873 Abel MK, Shui AM, Melisko M et al (2021) The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study. NPJ Breast Cancer 7:156. https://doi.org/10.1038/S41523-021-00366-X Sledge GW, Chagpar A, Perou C (2016) Collective Wisdom: Lobular Carcinoma of the Breast. Am Soc Clin Oncol Educational Book 35:18–21. https://doi.org/10.14694/edbk_100002 Mamtani A, King TA (2018) Lobular Breast Cancer: Different Disease, Different Algorithms? Surg Oncol Clin N Am 27:81–94. https://doi.org/10.1016/j.soc.2017.07.005 Lips EH, Mukhtar RA, Yau C et al (2012) Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat 136:35–43. https://doi.org/10.1007/s10549-012-2233-z Rakha EA, El-Sayed ME, Powe DG et al (2008) Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes. Eur J Cancer 44:73–83. https://doi.org/10.1016/j.ejca.2007.10.009 Adachi Y, Ishiguro J, Kotani H et al (2016) Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. BMC Cancer 16. https://doi.org/10.1186/s12885-016-2275-4 Thomas M, Kelly ED, Abraham J, Kruse M (2019) Invasive lobular breast cancer: A review of pathogenesis, diagnosis, management, and future directions of early stage disease. Semin Oncol 46:121–132. https://doi.org/10.1053/j.seminoncol.2019.03.002 Bilimoria KY, Bentrem DJ, Stewart AK et al (2009) Comparison of Commission on Cancer-approved and -nonapproved hospitals in the United States: Implications for studies that use the National Cancer Data Base. J Clin Oncol 27:4177–4181. https://doi.org/10.1200/JCO.2008.21.7018 Boffa DJ, Rosen JE, Mallin K et al (2017) Using the national cancer database for outcomes research a review. JAMA Oncol 3:1722–1728. https://doi.org/10.1001/jamaoncol.2016.6905 Sparano JA, Gray RJ, Makower DF et al (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111–121. https://doi.org/10.1056/NEJMOA1804710 Olivotto IA, Bajdik CD, Ravdin PM et al (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin oncology: official J Am Soc Clin Oncol 23:2716–2725. https://doi.org/10.1200/JCO.2005.06.178 Ravdin PM, Siminoff LA, Davis GJ et al (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980–991. https://doi.org/10.1200/JCO.2001.19.4.980 Mook S, Schmidt MK, Rutgers EJ et al (2009) Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol 10:1070–1076. https://doi.org/10.1016/S1470-2045(09)70254-2 Sparano JA, Gray RJ, Ravdin PM et al (2019) Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. N Engl J Med 380:2395–2405. https://doi.org/10.1056/NEJMOA1904819/ . SUPPL_FILE/NEJMOA1904819_DATA-SHARING.PDF National Cancer Database Participant User File (2022) 2018 Data Dictionary. https://www.facs.org/-/media/files/quality-programs/cancer/ncdb/puf_data_dictionary.ashx . Accessed 1 Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619. https://doi.org/10.1016/0895-4356(92)90133-8 Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J chronic Dis 40:373–383. https://doi.org/10.1016/0021-9681(87)90171-8 Marmor S, Hui JYC, Huang JL et al (2017) Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast. Cancer 123:3015–3021. https://doi.org/10.1002/cncr.30699 Tamirisa N, Williamson H, Thomas SM et al (2019) The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma. J Surg Oncol 120:132–141. https://doi.org/10.1002/jso.25492 Trapani D, Gandini S, Corti C et al (2021) Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. Cancer Treat Rev 97. https://doi.org/10.1016/J.CTRV.2021.102205 Dowsett M, Sestak I, Regan MM et al (2018) Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin Oncol 36:1941–1948. https://doi.org/10.1200/JCO.2017.76.4258 Pan H, Gray R, Braybrooke J et al (2017) 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med 377:1836–1846. https://doi.org/10.1056/NEJMOA1701830/SUPPL_FILE/NEJMOA1701830_DISCLOSURES.PDF McCart Reed AE, Lal S, Kutasovic JR et al (2019) LobSig is a multigene predictor of outcome in invasive lobular carcinoma. npj Breast Cancer 2019 5(1):1–11. https://doi.org/10.1038/s41523-019-0113-y Ciriello G, Gatza ML, Beck AH et al (2015) Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell 163:506–519. https://doi.org/10.1016/J.CELL.2015.09.033 Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-1322653","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":82183804,"identity":"1dd8a5fa-701a-47b5-90df-56fe43c56f73","order_by":0,"name":"Mary Kathryn Abel","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABDUlEQVRIiWNgGAWjYJACxgYGhgQYS4YfxKiAiOLTYgDXwiMJUnqGJC0GBwho0W0/+0xyRs2fPPMZuQcYfu6w4TG+kfz4wwEGG9kNB7BrMTuTbia54ZhBscyNvATG3jNpPGY30swkDjCkGePUciCNTfIBm0HiDIkcAwbetsNALTlszB8YDifi1HL+GVDLP4gWxr9t/3mMZ+QwAx32H7eWG0BbNrZBtDDzth3gMZDIYQA67AAeLc+YLWf2GSfO4HljcFj2TDKPxJlnQL8YJBvPxOmwNMabPd/kEmew5xg+fLvDTo6/HRRiFXayfTi0AAGLBJgSSGBAUmOAUzkIAIMHBPhxGzoKRsEoGAUjHAAABYtldEUCt44AAAAASUVORK5CYII=","orcid":"https://orcid.org/0000-0003-0447-5823","institution":"University of California San Francisco School of Medicine","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Mary","middleName":"Kathryn","lastName":"Abel","suffix":""},{"id":82183805,"identity":"99656528-dbeb-4570-bbb0-da853960af56","order_by":1,"name":"Amy S Shui","email":"","orcid":"","institution":"University of California San Francisco School of Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Amy","middleName":"S","lastName":"Shui","suffix":""},{"id":82183806,"identity":"c7f004d1-b9dd-455f-8562-ec9e9fa60305","order_by":2,"name":"A. Jo Chien","email":"","orcid":"","institution":"University of California San Francisco School of Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"A.","middleName":"Jo","lastName":"Chien","suffix":""},{"id":82183807,"identity":"5142146d-b3c3-4398-aef9-62055ab19bf9","order_by":3,"name":"Hope S. Rugo","email":"","orcid":"","institution":"University of California San Francisco School of Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Hope","middleName":"S.","lastName":"Rugo","suffix":""},{"id":82183808,"identity":"9ae1d5d5-b8a7-472c-85be-e8503558bbcc","order_by":4,"name":"Michelle Melisko","email":"","orcid":"","institution":"University of California San Francisco School of Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Michelle","middleName":"","lastName":"Melisko","suffix":""},{"id":82183809,"identity":"9dcafc65-0b56-4db2-996c-017db3a7de03","order_by":5,"name":"Frederick Baehner","email":"","orcid":"","institution":"University of California San Francisco School of Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Frederick","middleName":"","lastName":"Baehner","suffix":""},{"id":82183810,"identity":"eebe9e26-151a-4284-bdcd-7deeb81c47d8","order_by":6,"name":"Rita A. Mukhtar","email":"","orcid":"https://orcid.org/0000-0001-8079-7846","institution":"University of California San Francisco School of Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Rita","middleName":"A.","lastName":"Mukhtar","suffix":""}],"badges":[],"createdAt":"2022-02-03 04:37:30","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-1322653/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-1322653/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":18068606,"identity":"468d06f9-dfea-4fc8-88f4-72f593409eb7","added_by":"auto","created_at":"2022-02-09 16:17:46","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":104936,"visible":true,"origin":"","legend":"\u003cp\u003eCONSORT Diagram for Study Population\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eLegend\u003c/strong\u003e: CONSORT diagram for study. NCDB = National Cancer Database; HR = hormone receptor; HER2 = human epidermal growth factor-receptor 2\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-1322653/v1/d2cd76f2e5cfa85d957c3baa.png"},{"id":18068605,"identity":"f44ccd0c-c9a6-4435-b742-b304f1c9d9c9","added_by":"auto","created_at":"2022-02-09 16:17:46","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":41728,"visible":true,"origin":"","legend":"\u003cp\u003eProportion of patients who received chemotherapy by histology, nodal status, and recurrence score.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eLegend\u003c/strong\u003e: ILC = invasive lobular carcinoma; IDC = invasive ductal carcinoma; RS = recurrence score. Chi-square test comparing patients with ILC/RS \u0026gt; 25/node negative vs. IDC/RS \u0026gt; 25/node negative and ILC/RS \u0026gt; 25/1-3 positive nodes vs. IDC/RS \u0026gt; 25/1-3 positive nodes both yielded p \u0026lt; 0.001. All other comparisons were not statistically significant.\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-1322653/v1/ec7357228e86a23b5bc708f6.png"},{"id":18068712,"identity":"5e7aeba6-d875-49fe-8eb4-da560aa77207","added_by":"auto","created_at":"2022-02-09 16:20:46","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":27692,"visible":true,"origin":"","legend":"\u003cp\u003ePropensity score matched analysis using greedy fixed matching method comparing overall survival in individuals who received chemotherapy compared to those who did not among patients with 1-3 positive nodes and RS £ 25 by histology. For patients with IDC, survival between those who did received chemotherapy and those who did not was not significantly different from one another (stratified log-rank test p = 0.278, Figure 3a). Similarly, for patients with ILC, survival between those who did received chemotherapy and those who did not was not significantly different from one another (stratified log-rank test p = 0.532, Figure 3b).\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eLegend\u003c/strong\u003e: ILC = invasive lobular carcinoma; IDC = invasive ductal carcinoma; RS = recurrence score. Survival estimates of in individuals who received chemotherapy (blue solid line) compared to those who did not (red dotted line) among patients with 1-3 positive nodes and RS £ 25 by histology.\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-1322653/v1/1db599a0a332cb5e4fff3d82.png"},{"id":19174852,"identity":"6098dc3f-29d4-40e2-8a18-bcb9b23b3e8f","added_by":"auto","created_at":"2022-03-13 19:16:21","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":538474,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-1322653/v1/3527c010-0191-4412-be80-2bb732f30c82.pdf"}],"financialInterests":"","formattedTitle":"The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study","fulltext":[{"header":"Introduction","content":"\u003cp\u003eDespite major advances in the treatment of breast cancer, personalizing therapy to reduce recurrence risk while minimizing harm remains a challenge. Recommendations for treatment such as adjuvant chemotherapy rely upon multiple factors, including patient characteristics and overall health status, tumor features, and often molecular assays such as the 70-gene signature or the 21-gene Recurrence Score (RS) [\u003cspan additionalcitationids=\"CR2\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. When patient and tumor factors suggest a high risk of recurrence, patients are deemed to have high \u0026ldquo;clinical\u0026rdquo; risk, and chemotherapy may be considered. Similarly, when molecular assays suggest a high risk of recurrence, tumors are considered to have high \u0026ldquo;genomic\u0026rdquo; risk, and patients with these high-risk tumors are predicted to benefit from chemotherapy.\u003c/p\u003e \u003cp\u003eHowever, when clinical and genomic risk are discordant, decisions about the efficacy of chemotherapy become more difficult. In the recently published RxPONDER trial, chemotherapy did not improve invasive disease-free survival in clinically high-risk post-menopausal patients with low genomic risk (based on RS \u0026le; 25), although benefit was seen in those who were pre-menopausal [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. These findings illustrate some of the challenges of treatment selection for those with discordant clinical and genomic risk.\u003c/p\u003e \u003cp\u003eWe previously showed that such discordant risk status disproportionately affects patients with invasive lobular carcinoma (ILC) compared to invasive ductal carcinoma (IDC) when genomic risk is evaluated with 70-gene signature testing [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. As the second most common histologic subtype of breast cancer, ILC is thought to have a more indolent course but often presents at higher stages with considerable cumulative risk of late recurrence [\u003cspan additionalcitationids=\"CR7 CR8 CR9 CR10\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. We therefore sought to investigate rates of discordant clinical and genomic risk by histologic subtype in patients who underwent RS testing in the National Cancer Database.\u003c/p\u003e \u003cp\u003eSpecifically, we evaluated the following questions: (1) whether patients with ILC are more likely to have discordant clinical and genomic risk than those with IDC using the 21-gene RS; (2) whether use of chemotherapy differs by histologic subtype stratified by clinical and genomic risk category; and (3) whether patients with 1-3 positive nodes and RS \u0026le; 25 have different overall survival outcomes with or without adjuvant chemotherapy stratified by histologic subtype.\u003c/p\u003e"},{"header":"Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eData Source and Study Cohort\u003c/h2\u003e \u003cp\u003eOur study cohort consisted of patients in the National Cancer Database (NCDB). The NCDB is a national comprehensive clinical surveillance resource and represents over 70% of all newly diagnosed cancer cases in the United States [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. Participants User Files from 2010-2016 were used in our analysis. Due to the de-identified nature of the public-access user files, the study did not require institutional review board approval.\u003c/p\u003e \u003cp\u003eWe limited our analysis to patients with invasive HR positive and human epidermal growth factor-receptor 2 (HER2) negative tumors with an available 21-gene RS result. We excluded patients with stage IV disease, those who received neoadjuvant therapy, individuals who did not undergo surgery for breast cancer, and those who were missing critical clinical information including histologic subtype, tumor grade, number of positive lymph nodes on pathology, tumor size, and timing of chemotherapy or endocrine therapy.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eClinical Measures and Outcomes\u003c/h2\u003e \u003cp\u003eOur primary outcome was the rate of discordant clinical and genomic risk status by histologic subtype. We assigned clinical risk using a modified Adjuvant! Online calculator as described in the MINDACT trial; we also categorized patients by number of positive lymph nodes on surgical pathology (0, 1-3, or \u0026gt;3 nodes) [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan additionalcitationids=\"CR15\" citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. The modified Adjuvant! Online risk score includes tumor size, tumor grade, and number of positive lymph nodes identified at surgery; those with a 92% or greater probability of breast-cancer specific survival at 10 years without chemotherapy were deemed to have low clinical risk [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. We assigned genomic risk using the 21-gene RS result, with RS \u0026gt; 25 considered as high genomic risk and RS \u0026le; 25 as low genomic risk, consistent with RxPONDER.\u003c/p\u003e \u003cp\u003eHistologic subtype was determined by defined codes in the NCDB. The ILC cohort included codes for ILC or mixed ILC/IDC (histology codes 8520 and 8524 if behavior was invasive). The IDC cohort comprised codes for IDC or invasive mammary carcinoma not otherwise specified (histology codes 8500, 8501, 8502, 8503, and 8523 if behavior was invasive). Menopausal status was approximated using age under 50 years (pre-menopausal) and over 50 years (post-menopausal) and included as a predictor in our model. Additionally, the Charlson-Deyo Co-Morbidity Index was used as a marker of severity of co-morbid conditions. The Charlson-Deyo Co-Morbidity Index is a weighted score from 0-3 derived from multiple comorbid conditions, including myocardial infarction, diabetes, and renal disease, with higher score reflecting more comorbid disease [\u003cspan additionalcitationids=\"CR20\" citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eStatistical Analysis\u003c/h2\u003e \u003cp\u003ePatient characteristics were described and differences between histologic subtype were evaluated using chi-square tests for categorical variables and t-tests for continuous variables. Additionally, the frequency of patients in each of the four clinical and genomic risk categories (clinical high/genomic low, clinical low/genomic low, clinical high/genomic high, clinical low/genomic high) was described by histologic subtype, with chi-square testing used to compare the clinical high/genomic low risk cohort compared to other risk categories combined and across all four risk categories. We also performed subgroup analyses evaluating concordance of genomic and clinical risk by categorical nodal status, histology, and age. Receipt of chemotherapy stratified by histology, nodal status, RS, and age was also assessed. All analyses were pre-specified.\u003c/p\u003e \u003cp\u003eFinally, propensity score matching was used to compare 60-month overall survival in individuals who did and did not receive chemotherapy among patients with 1-3 positive nodes and RS \u0026le; 25, stratified by histology. A greedy, fixed 1:1 matching method was used, and patients were matched by age at diagnosis in years, pathologic stage of disease (stage 2/3 vs. stage 1), and facility type. The upper limit of the absolute values of weighted matched standardized mean differences was set at 0.2. While we planned a pre-specified propensity score matched analysis evaluating the relationship between chemotherapy and overall survival in the subgroup of women aged under 50 years, with 1-3 positive nodes, and RS \u0026le; 25, there were too few patients to allow for matching. We therefore performed exploratory analyses evaluating overall survival with and without chemotherapy using the log-rank test in this subgroup of women, stratified by histology; we also used the Cox proportional hazards model to evaluate overall survival both unadjusted and adjusted for Charlson-Deyo Co-Morbidity Index.\u003c/p\u003e \u003cp\u003eHypothesis tests were two-sided, and the significance threshold was set to 0.05. Statistical analyses were performed using Stata 16 and SAS version 9.4.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cp\u003eA total of 2,696,734 patients with breast cancer were included in the original NCDB database. After excluding patients based on the criteria previously described, there were 186,867 patients with stage I-III, HR positive, HER2 negative disease without neoadjuvant therapy who underwent breast surgery and received 21-gene RS testing that were included in our analysis (Figure \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e). Of these, 149,182 (79.8%) patients had IDC, and 37,685 (20.2%) patients had ILC.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cdiv id=\"Sec7\" class=\"Section2\"\u003e\n\u003ch2\u003eILC versus IDC Cohorts\u003c/h2\u003e\n\u003cp\u003ePatients in the ILC cohort were slightly older than those in the IDC cohort (mean age 60.5 years versus 58.9, p\u0026lt;0.001). Additionally, they were more likely to present with higher stage disease and underwent mastectomy at higher rates (Table \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e). The ILC tumors were significantly less likely to be grade 3, and overall chemotherapy was used less often in the ILC cohort compared to those with IDC. There was also a statistically significant difference in Charlson-Deyo score between the ILC and IDC cohorts, with ILC patients as more likely to have a Charlson-Deyo score of 0 compared to those with IDC (85.0% vs. 84.5%, p=0.015).\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n\u003ctable id=\"Tab1\" border=\"1\"\u003e\u003ccaption\u003e\n\u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\n\u003cdiv class=\"CaptionContent\"\u003e\n\u003cp\u003eClinicopathologic characteristics of study cohort.\u003c/p\u003e\n\u003c/div\u003e\n\u003c/caption\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003e\u0026nbsp;\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eILC\u003c/p\u003e\n\u003cp\u003e(N = 37,685)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eIDC\u003c/p\u003e\n\u003cp\u003e(N = 149,182)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eP-Value\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eAge at diagnosis (years), mean (SD)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e60.5 (10.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e58.9 (10.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePathologic stage, n (%)\u003c/p\u003e\n\u003cp\u003eI\u003c/p\u003e\n\u003cp\u003eII\u003c/p\u003e\n\u003cp\u003eIII\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e21,384 (56.7)\u003c/p\u003e\n\u003cp\u003e15,302 (40.6)\u003c/p\u003e\n\u003cp\u003e999 (2.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e104,748 (70.2)\u003c/p\u003e\n\u003cp\u003e43,194 (29.0)\u003c/p\u003e\n\u003cp\u003e1,240 (0.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eNodal involvement\u003c/p\u003e\n\u003cp\u003eNode negative\u003c/p\u003e\n\u003cp\u003e1-3 positive\u003c/p\u003e\n\u003cp\u003e\u0026gt;3 positive\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e30,401 (80.7)\u003c/p\u003e\n\u003cp\u003e6,869 (18.2)\u003c/p\u003e\n\u003cp\u003e415 (1.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e123,470 (82.8)\u003c/p\u003e\n\u003cp\u003e24,919 (16.7)\u003c/p\u003e\n\u003cp\u003e793 (0.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt;0.001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eTumor grade, n (%)\u003c/p\u003e\n\u003cp\u003e1\u003c/p\u003e\n\u003cp\u003e2\u003c/p\u003e\n\u003cp\u003e3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e9,451 (25.1)\u003c/p\u003e\n\u003cp\u003e25,403 (67.4)\u003c/p\u003e\n\u003cp\u003e2,831 (7.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e43,276 (29.0)\u003c/p\u003e\n\u003cp\u003e78,871 (52.9)\u003c/p\u003e\n\u003cp\u003e27,035 (18.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eClinical risk, n (%)\u003c/p\u003e\n\u003cp\u003eLow\u003c/p\u003e\n\u003cp\u003eHigh\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e21,464 (57.0)\u003c/p\u003e\n\u003cp\u003e16,221 (43.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e96,060 (64.4)\u003c/p\u003e\n\u003cp\u003e53,122 (35.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eGenomic risk, n (%)\u003c/p\u003e\n\u003cp\u003e21-gene RS \u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\u0026le;\u003c/span\u003e\u003c/span\u003e 25\u003c/p\u003e\n\u003cp\u003e21-gene RS \u0026gt; 25\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e34,534 (91.6)\u003c/p\u003e\n\u003cp\u003e3,151 (8.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e125,030 (83.8)\u003c/p\u003e\n\u003cp\u003e24,152 (16.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eSurgical therapy, n (%)\u003c/p\u003e\n\u003cp\u003eLumpectomy\u003c/p\u003e\n\u003cp\u003eMastectomy\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e21,373 (56.7)\u003c/p\u003e\n\u003cp\u003e16,312 (43.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e102,467 (68.7)\u003c/p\u003e\n\u003cp\u003e46,715 (31.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eAdjuvant therapy, n (%)\u003c/p\u003e\n\u003cp\u003eChemotherapy\u003c/p\u003e\n\u003cp\u003eEndocrine Therapy\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e6,383 (17.3)\u003c/p\u003e\n\u003cp\u003e35,161 (94.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e33,534 (22.9)\u003c/p\u003e\n\u003cp\u003e137,003 (93.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n\u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eCharlson-Deyo Score, n (%)\u003c/p\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003cp\u003e1\u003c/p\u003e\n\u003cp\u003e2\u003c/p\u003e\n\u003cp\u003e\u0026ge;3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e32,039 (85.0)\u003c/p\u003e\n\u003cp\u003e4,629 (12.3)\u003c/p\u003e\n\u003cp\u003e799 (2.1)\u003c/p\u003e\n\u003cp\u003e218 (0.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e126,007 (84.5)\u003c/p\u003e\n\u003cp\u003e18,834 (12.6)\u003c/p\u003e\n\u003cp\u003e3,312 (2.2)\u003c/p\u003e\n\u003cp\u003e1,029 (0.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.015\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eLegend\u003c/strong\u003e: ILC = invasive lobular carcinoma; IDC = invasive ductal carcinoma; RS = recurrence score\u003c/p\u003e\n\u003c/div\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e\n\u003ch2\u003eClinical and Genomic Risk Discordance\u003c/h2\u003e\n\u003cp\u003eWe found a significantly higher rate of discordant clinical and genomic risk in patients with ILC compared to IDC. Patients with ILC were more likely to have high clinical risk by modified Adjuvant! Online than those with IDC (43% versus 35.6%, p\u0026lt;0.001, Table \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e). Consistent with this finding, those with ILC were less likely to be node negative than those with IDC (80.7% versus 82.8%, p\u0026lt;0.001). While clinical risk was higher in ILC patients, genomic risk by RS was much lower, with an incidence of RS \u0026gt; 25 in ILC patients of 8.4% compared to 16.2% in IDC patients (p\u0026lt;0.001). Together, this resulted in significantly higher rates of discordant clinical and genomic risk, with 37.8% of the ILC group being clinical high/genomic low compared to 24.9% of the IDC group (p\u0026lt;0.001, Table \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n\u003ctable id=\"Tab2\" border=\"1\"\u003e\u003ccaption\u003e\n\u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e\n\u003cdiv class=\"CaptionContent\"\u003e\n\u003cp\u003eDistribution of clinical and genomic risk categories by histology. Genomic risk was categorized as either 21-gene RS \u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\u0026le;\u003c/span\u003e\u003c/span\u003e 25 or 21-gene RS \u0026gt; 25.\u003c/p\u003e\n\u003c/div\u003e\n\u003c/caption\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003e\u0026nbsp;\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eILC\u003c/p\u003e\n\u003cp\u003e(n = 37,685)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eIDC\u003c/p\u003e\n\u003cp\u003e(n = 149,182)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eP-Value\u003csup\u003e1\u003c/sup\u003e\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eP-Value\u003csup\u003e2\u003c/sup\u003e\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eClinical high/21-gene RS \u0026le; 25\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e14,253 (37.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e37,126 (24.9)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"2\" align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"5\" align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt;0.001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eOther\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e23,432 (62.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e112,056 (75.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eClinical low/21-gene RS \u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\u0026le;\u003c/span\u003e\u003c/span\u003e 25\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e19,601 (52.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e85,078 (57.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eClinical high/21-gene RS \u0026gt; 25\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e1,968 (5.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e15,996 (10.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eClinical low/21-gene RS \u0026gt; 25\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e1,863 (4.9)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e10,982 (7.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eLegend\u003c/strong\u003e: ILC = invasive lobular carcinoma, IDC = invasive ductal carcinoma. \u003csup\u003e1\u003c/sup\u003eP-value from chi square comparing clinical high / genomic low compared to other risk categories combined. \u003csup\u003e2\u003c/sup\u003eP-value from chi square comparing across all four risk categories.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/div\u003e\n\u003cp\u003eWithin the group of patients with 1-3 positive nodes, patients with ILC were significantly more likely to have a RS \u0026le; 25 compared to those with IDC (92.5% versus 85.8% respectively, p\u0026lt;0.001, Table \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003e). This difference was more pronounced in those with \u0026gt;3 positive nodes, with the vast majority of ILC patients in this group (90.1%) having a RS \u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\u0026le;\u003c/span\u003e\u003c/span\u003e 25 compared to 78.3% in the IDC group (p\u0026lt;0.001, Table \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003e). Interestingly, among patients under the age of 50, ILC patients remained significantly more likely to have RS \u0026le; 25 than those with IDC across all nodal involvement categories. In patients under age 50 with 1-3 positive nodes, low RS occurred in 94.8% of ILC group versus 85.1% of IDC group; among the small number of patients with \u0026gt;3 positive nodes, low RS occurred in 94.7% of ILC group versus 70.6% of IDC group (both p\u0026lt;0.001, Table \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n\u003ctable id=\"Tab3\" border=\"1\"\u003e\u003ccaption\u003e\n\u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e\n\u003cdiv class=\"CaptionContent\"\u003e\n\u003cp\u003eBreakdown of nodal status by histology and 21-gene recurrence score in all patients (top) and for those with age less than 50 years (bottom).\u003c/p\u003e\n\u003c/div\u003e\n\u003c/caption\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eAll Patients\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eILC Overall (n)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eIDC Overall (n)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eILC 21-Gene RS\u003c/p\u003e\n\u003cp\u003e\u0026le; 25 (n [%])\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eIDC 21-Gene RS\u003c/p\u003e\n\u003cp\u003e\u0026le; 25 (n [%])\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eP-Value\u003csup\u003e1\u003c/sup\u003e\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eNode Negative\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e30,401\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e123,470\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e27,804 (91.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e103,039 (83.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1-3 Positive Nodes\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e6,869\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e24,919\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e6,356 (92.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e21,370 (85.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026gt; 3 Positive Nodes\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e415\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e793\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e374 (90.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e621 (78.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003c/div\u003e\n\u003cdiv class=\"gridtable\"\u003e\n\u003ctable id=\"Taba\" border=\"1\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003ePatients Age \u0026lt; 50 Years\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eILC Overall (n)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eIDC Overall (n)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eILC 21-Gene RS\u003c/p\u003e\n\u003cp\u003e\u0026le; 25 (n [%])\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eIDC 21-Gene RS\u003c/p\u003e\n\u003cp\u003e\u0026le; 25 (n [%])\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eP-Value\u003csup\u003e1\u003c/sup\u003e\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eNode Negative\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e4,911\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e26,038\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e4,644 (94.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e22,016 (84.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1-3 Positive Nodes\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e1,120\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e4,996\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e1,062 (94.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e4,251 (85.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026gt; 3 Positive Nodes\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e57\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e163\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e54 (94.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e115 (70.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eLegend\u003c/strong\u003e: ILC = invasive lobular carcinoma, IDC = invasive ductal carcinoma, RS = recurrence score. \u003csup\u003e1\u003c/sup\u003eP-value from chi square comparing ILC 21-gene RS \u0026le; 25 and 21-gene IDC RS \u0026le; 25 across nodal categories.\u003c/p\u003e\n\u003c/div\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec9\" class=\"Section2\"\u003e\n\u003ch2\u003eChemotherapy Use\u003c/h2\u003e\n\u003cp\u003eWe then evaluated the receipt of chemotherapy by histology, nodal status, RS category, and age. Among patients with RS \u0026le; 25, there was no difference in receipt of chemotherapy by histology across the node negative, 1-3 positive nodes, and \u0026gt;3 positive nodal groups (Figure \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e). However, among patients with RS \u0026gt; 25, those with ILC were significantly less likely to receive chemotherapy than those with IDC among patients with negative nodes or 1-3 positive nodes (both p\u0026lt;0.001). In those with high clinical risk and RS \u0026gt; 25, chemotherapy was used significantly more often in patients under 50 years old compared to those age 50 years or older, in both ILC and IDC groups. However, among clinically high risk patients with RS \u0026gt; 25 and age over 50 years, those with ILC were still less likely to receive chemotherapy than those with IDC (63.3% versus 74.8%, p\u0026lt;0.001). In ILC patients with high clinical risk and RS \u0026gt; 25, 88.7% of patients were age 50 years or older, and 63.3% received chemotherapy compared to 80.5% of those under age 50 years (p\u0026lt;0.001). Among IDC patients with high clinical risk and RS \u0026gt; 25, 78.2% of patients were age 50 years or older, and 74.8% received chemotherapy compared to 88.2% of those under age 50 years (p\u0026lt;0.001).\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec10\" class=\"Section2\"\u003e\n\u003ch2\u003eOverall Survival Outcomes\u003c/h2\u003e\n\u003cp\u003eFinally, we performed a propensity score matched analysis to compare overall survival in individuals who received chemotherapy compared to those who did not receive chemotherapy by histology among those with 1-3 positive nodes and RS \u0026le; 25, including patients of all ages. The absolute values of the weighted matched standardized mean differences were less than the recommended upper limit of 0.2, and all weighted matched variance ratios were between 0.5 and 2. Among patients with IDC, there was no statistically significant difference in survival between those who did and did not receive chemotherapy (stratified log-rank test p=0.278, Figure 3a). Similarly, for patients with ILC, survival between those who did receive chemotherapy and those who did not receive chemotherapy was not significantly different from one another (stratified log-rank test p=0.532, Figure 3b). There were too few patients under the age of 50 years to perform a propensity score matched analysis, so exploratory results from unmatched survival analyses are reported. For women under age 50, with 1-3 positive nodes, and RS \u0026le; 25, unadjusted analysis showed that chemotherapy was associated with a significant improvement in overall survival for those with IDC (hazard ratio [HR] 0.44, 95% confidence interval [CI] 0.22-0.86, p=0.016) but not for those with ILC (HR 0.54, 95% CI 0.14-2.18, p=0.39). The association between chemotherapy and improved overall survival in those with IDC persisted when adjusted for Charlson-Deyo Index (HR 0.44, 95% CI 0.22-0.85, p=0.016). There was no statistical interaction between chemotherapy and histology on overall survival.\u003c/p\u003e\n\u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn this study of 186,867 patients with HR positive, HER2-negative invasive breast cancer who underwent 21-gene RS testing in the National Cancer Database, we found that patients with ILC have higher rates of discordant clinical and genomic risk than those with IDC. This finding is consistent with our prior work, which showed higher rates of discordant clinical and genomic risk in ILC patients using the 70-gene signature [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. Additionally, we found that ILC patients with 1-3 positive nodes were significantly more likely to have RS \u0026le; 25 compared to those with IDC, in both those under age 50 years and those age 50 years or older.\u003c/p\u003e \u003cp\u003eAmong those with RS \u0026le; 25, there was no difference in receipt of chemotherapy by histology regardless of nodal involvement. However, among those with RS \u0026gt;25, those with ILC were significantly less likely to receive chemotherapy than those with IDC among patients with negative nodes or 1-3 positive nodes. While these findings are consistent with our prior study, which showed lower rates of chemotherapy use in patients with high clinical risk ILC and high genomic risk as defined by 70-gene signature testing, they are nonetheless surprising given the general acceptance of chemotherapy in the setting of RS \u0026gt; 25 and did not appear to be driven by older age in the ILC group [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. These findings may reflect hesitation on the part of clinicians and patients to utilize chemotherapy in ILC, where multiple studies have shown less benefit in the neoadjuvant and adjuvant settings [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. Together, this illustrates the treatment dilemma that clinicians and patients face: while patients with ILC are more likely to have high clinical risk, which portends increased risk of recurrence without chemotherapy, genomic assays and reported series suggest decreased chemotherapy benefit [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eWe did not demonstrate any effect of chemotherapy on overall survival among patients with 1-3 positive nodes and RS \u0026le; 25 in our propensity score matched analyses, regardless of histologic subtype. Interestingly, we did find an association between chemotherapy and overall survival in unmatched analysis of IDC patients under age 50 with 1-3 positive nodes and RS \u0026le; 25, but not among those under age 50 with ILC. Given the retrospective nature of this analysis, differences in patient selection for receiving chemotherapy likely contribute to chemotherapy related outcomes. While we attempted to account for potential confounders in treatment selection by using propensity score matching by age at diagnosis, pathologic stage, and facility type, it is unlikely that we were able to fully adjust for potential bias between the chemotherapy and non-chemotherapy groups.\u003c/p\u003e \u003cp\u003eThis bias is greater in our exploratory unmatched analysis in patients under age 50, which showed a significant improvement in overall survival among IDC patients who received chemotherapy compared to those who did not but no difference in those with ILC. There are several potential explanations for the findings of our exploratory analyses. One possibility is that among those under age 50 with 1-3 positive nodes and RS \u0026le; 25, the overall survival difference observed in the IDC group resulted from patient selection bias and not chemotherapy effect. Another explanation is that we were unable to detect an overall survival benefit in the ILC patients under age 50, with 1-3 positive nodes, and RS \u0026le; 25 because of small numbers in this subgroup. Lastly, it is possible that chemotherapy improves overall survival in IDC patients but not ILC patients under the age of 50 with 1-3 positive nodes and RS \u0026le; 25; for this reason, reporting of long-term and overall survival outcomes by histologic subtype from trials such as RxPONDER is needed.\u003c/p\u003e \u003cp\u003eWhile the RxPONDER trial showed a significant improvement in invasive disease-free survival in patients under age 50 who had 1-3 positive nodes and RS \u0026le; 25 who received chemotherapy, we cannot directly compare our results since the National Cancer Database lacks recurrence endpoints. It is important to note that for patients with HR positive HER2 negative tumors, and ILC especially, recurrence events and consequently impact on overall survival can happen at later timepoints, highlighting the need for longer term follow-up [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. Additionally, we lacked data on type of endocrine therapy which likely impacts outcomes.\u003c/p\u003e \u003cp\u003eThis study has many strengths, including the use of a relatively large numbers of ILC patients, and is now the second study to demonstrate that patients with ILC have high rates of discordance between clinical and genomic risk based on widely used molecular assays. While many studies show that ILC tumors have lower response rates to chemotherapy in the neoadjuvant setting, and less benefit from chemotherapy in the adjuvant setting, there may still be a subset of chemotherapy sensitive ILC cases. Recent work has identified genomic signatures that identify subtypes within ILC, suggesting heterogeneity within this tumor type [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e, \u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]. The high incidence of high clinical risk among patients with ILC highlights the need for both more effective therapies, and potentially ILC specific prediction tools. More broadly, improving outcomes for these patients with ILC will require not only equitable enrollment of ILC patients into breast cancer clinical trials, but also histologic subtype specific reporting of trial results.\u003c/p\u003e"},{"header":"Declarations","content":"\n\u003cp\u003eAmy M. Shui is part of the Biostatistics Core that is generously supported by the UCSF Department of Surgery.\u0026nbsp;\u003c/p\u003e\n\u003cp id=\"isPasted\"\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eDr. Rita A. Mukhtar is supported by National Cancer Institute Award K08CA256047. The other authors declare that no funds, grants, or other support were received during the preparation of this manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting Interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eDr. A. Jo Chien receives research funding from Merck,\u0026nbsp;Puma, Amgen, and Seattle Genetics.\u0026nbsp;Dr. Hope S. Rugo receives research support for clinical trials through the University of California from Pfizer, Merck, Novartis, Lilly, Roche, Odonate, Daiichi, Seattle Genetics, Macrogenics, Sermonix, Astra Zeneca, OBI, Gilead, and Ayala. She has also received honoraria from Puma, Samsung, and Napo. Dr. Michelle Melisko receives research funding from Astra Zeneca, Novartis, KCRN Research, and Puma and consulting fees from Biotheranostics. Dr.\u0026nbsp;Baehner\u0026nbsp;is the Chief Medical Officer of Precision Oncology at Exact Sciences. The remaining authors declare no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor Contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Mary Kathryn Abel, Amy M. Shui, and Dr. Rita A. Mukhtar. The first draft of the manuscript was written by Mary Kathryn Abel and Dr. Rita A. Mukhtar, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData Availability\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe data that support the findings of this study are available from the National Cancer Database (NCDB), but restrictions apply to the availability of these data, which were used under license for the current study and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the NCDB.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics Approval\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eOur study was deemed exempt by University of California, San Francisco institutional review board.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent to Participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent to Publish\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eVan\u0026rsquo;t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530\u0026ndash;536. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/415530a\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003evan de Vijver MJ, He YD, van \u0026rsquo;t Veer LJ et al (2002) A Gene-Expression Signature as a Predictor of Survival in Breast Cancer. N Engl J Med 347:1999\u0026ndash;2009. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1056/nejmoa021967\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCardoso F, van \u0026rsquo;t Veer L, Poncet C et al (2020) MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients. In:Journal of Clinical Oncology. p506\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKalinsky K, Barlow WE, Gralow JR et al (2021) 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med 385:2336\u0026ndash;2347. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1056/NEJMOA2108873\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAbel MK, Shui AM, Melisko M et al (2021) The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study. NPJ Breast Cancer 7:156. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/S41523-021-00366-X\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSledge GW, Chagpar A, Perou C (2016) Collective Wisdom: Lobular Carcinoma of the Breast. Am Soc Clin Oncol Educational Book 35:18\u0026ndash;21. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.14694/edbk_100002\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMamtani A, King TA (2018) Lobular Breast Cancer: Different Disease, Different Algorithms? Surg Oncol Clin N Am 27:81\u0026ndash;94. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.soc.2017.07.005\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLips EH, Mukhtar RA, Yau C et al (2012) Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat 136:35\u0026ndash;43. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s10549-012-2233-z\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRakha EA, El-Sayed ME, Powe DG et al (2008) Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes. Eur J Cancer 44:73\u0026ndash;83. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.ejca.2007.10.009\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAdachi Y, Ishiguro J, Kotani H et al (2016) Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. BMC Cancer 16. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1186/s12885-016-2275-4\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eThomas M, Kelly ED, Abraham J, Kruse M (2019) Invasive lobular breast cancer: A review of pathogenesis, diagnosis, management, and future directions of early stage disease. Semin Oncol 46:121\u0026ndash;132. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1053/j.seminoncol.2019.03.002\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBilimoria KY, Bentrem DJ, Stewart AK et al (2009) Comparison of Commission on Cancer-approved and -nonapproved hospitals in the United States: Implications for studies that use the National Cancer Data Base. J Clin Oncol 27:4177\u0026ndash;4181. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1200/JCO.2008.21.7018\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBoffa DJ, Rosen JE, Mallin K et al (2017) Using the national cancer database for outcomes research a review. JAMA Oncol 3:1722\u0026ndash;1728. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1001/jamaoncol.2016.6905\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSparano JA, Gray RJ, Makower DF et al (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111\u0026ndash;121. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1056/NEJMOA1804710\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOlivotto IA, Bajdik CD, Ravdin PM et al (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin oncology: official J Am Soc Clin Oncol 23:2716\u0026ndash;2725. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1200/JCO.2005.06.178\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRavdin PM, Siminoff LA, Davis GJ et al (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980\u0026ndash;991. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1200/JCO.2001.19.4.980\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMook S, Schmidt MK, Rutgers EJ et al (2009) Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol 10:1070\u0026ndash;1076. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/S1470-2045(09)70254-2\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSparano JA, Gray RJ, Ravdin PM et al (2019) Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. N Engl J Med 380:2395\u0026ndash;2405. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1056/NEJMOA1904819/\u003c/span\u003e\u003c/span\u003e. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003eSUPPL_FILE/NEJMOA1904819_DATA-SHARING.PDF\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNational Cancer Database Participant User File (2022) 2018 Data Dictionary. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.facs.org/-/media/files/quality-programs/cancer/ncdb/puf_data_dictionary.ashx\u003c/span\u003e\u003c/span\u003e. Accessed 1\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDeyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613\u0026ndash;619. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/0895-4356(92)90133-8\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCharlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J chronic Dis 40:373\u0026ndash;383. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/0021-9681(87)90171-8\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMarmor S, Hui JYC, Huang JL et al (2017) Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast. Cancer 123:3015\u0026ndash;3021. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/cncr.30699\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTamirisa N, Williamson H, Thomas SM et al (2019) The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma. J Surg Oncol 120:132\u0026ndash;141. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/jso.25492\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTrapani D, Gandini S, Corti C et al (2021) Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. Cancer Treat Rev 97. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/J.CTRV.2021.102205\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDowsett M, Sestak I, Regan MM et al (2018) Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin Oncol 36:1941\u0026ndash;1948. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1200/JCO.2017.76.4258\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePan H, Gray R, Braybrooke J et al (2017) 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med 377:1836\u0026ndash;1846. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1056/NEJMOA1701830/SUPPL_FILE/NEJMOA1701830_DISCLOSURES.PDF\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcCart Reed AE, Lal S, Kutasovic JR et al (2019) LobSig is a multigene predictor of outcome in invasive lobular carcinoma. npj Breast Cancer 2019 5(1):1\u0026ndash;11. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41523-019-0113-y\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCiriello G, Gatza ML, Beck AH et al (2015) Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell 163:506\u0026ndash;519. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/J.CELL.2015.09.033\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"invasive lobular carcinoma, invasive ductal carcinoma, chemotherapy, 21-gene recurrence score","lastPublishedDoi":"10.21203/rs.3.rs-1322653/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-1322653/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003ePurpose\u003c/strong\u003e: To evaluate whether patients with ILC are more likely to have discordant clinical and genomic risk than those with IDC when using the 21-gene recurrence score (RS), and to assess overall survival outcomes of patients with 1-3 positive nodes and RS ≤ 25 with and without chemotherapy, stratified by histology.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e: We performed a cohort study using the National Cancer Database and included patients with hormone receptor positive, HER2 negative, stage I-III invasive breast cancer who underwent 21-gene RS testing. Our primary outcome was rate of discordant clinical and genomic risk status by histologic subtype. Propensity score matching was used to compare 60-month overall survival in individuals with 1-3 positive nodes and RS £ 25 who did and did not receive chemotherapy.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eResults\u003c/strong\u003e: 186,867 patients were included in our analysis, including 37,685 (20.2%) patients with ILC. There was a significantly higher rate of discordant clinical and genomic risk in patients with ILC compared to IDC. Among patients with 1-3 positive nodes and RS ≤ 25, there was no significant difference in survival between those who did and did not receive chemotherapy in the IDC or ILC cohorts. Unadjusted exploratory analyses of patients under age 50 with 1-3 positive nodes and RS ≤ 25 showed improved overall survival in IDC patients who received chemotherapy, but not among those with ILC.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eConclusion\u003c/strong\u003e: Our findings highlight the importance of lobular-specific tools for stratifying clinical and genomic risk, as well as the need for histologic subtype-specific analyses in randomized trials.\u003c/p\u003e","manuscriptTitle":"The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2022-02-09 16:17:44","doi":"10.21203/rs.3.rs-1322653/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"9147903e-465c-4e1d-b927-24faed76fc34","owner":[],"postedDate":"February 9th, 2022","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2022-03-13T19:16:13+00:00","versionOfRecord":[],"versionCreatedAt":"2022-02-09 16:17:44","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-1322653","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-1322653","identity":"rs-1322653","version":["v1"]},"buildId":"WrCJVZZCHTDjtuVLN7oU0","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}